Knight W A, Fabian C, Costanzi J J, Jones S E, Coltman C A
Invest New Drugs. 1983;1(3):235-7. doi: 10.1007/BF00208895.
The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with lymphoma and Hodgkin's disease. Among 56 fully and partially evaluable patients responses were seen in 3 of 10 patients with Hodgkin's disease and 11 of 46 patients with lymphoma. Toxicity was acceptable. Methyl-GAG has significant antitumor activity among this group of heavily pretreated patients. Additional trials of methyl-GAG in combination with other agents are underway.
西南肿瘤协作组已对淋巴瘤和霍奇金病患者按每周一次的方案使用甲基甘氨酸铝。在56例可完全或部分评估的患者中，10例霍奇金病患者中有3例出现反应，46例淋巴瘤患者中有11例出现反应。毒性是可接受的。甲基甘氨酸铝在这群经过大量预处理的患者中具有显著的抗肿瘤活性。甲基甘氨酸铝与其他药物联合使用的进一步试验正在进行中。
